Sins of omission: how the US FDA's social media inaction puts patients and industry at risk
This article was originally published in SRA
Executive Summary
Eighteen months ago, 80 of my closest friends and I presented before the US Food and Drug Administration on how the agency should regulate the promotion of medical products via the internet and social media1. Not long after the November 2009 hearings, I wrote in this very publication:
You may also be interested in...
Sins of omission: how the US FDA's social media inaction puts patients and industry at risk
Eighteen months ago, 80 of my closest friends and I presented before the US Food and Drug Administration on how the agency should regulate the promotion of medical products via the internet and social media1. Not long after the November 2009 hearings, I wrote in this very publication: